



UCB Transparency Report - Luxembourg

Date of Publication June 3rd, 2024

	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of principal practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>	Donations and Grants to HCO's	Contribution to costs of Events			Fee for service and consultancy		Total optional	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities'consultation onli, as appropriate)												
							N/A	N/A					
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A	8403	11291			19694
Number of Recipients in aggregate disclosure						N/A	N/A	13	14	0	0		
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						N/A	N/A	100%	100%	%	%	100%	
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities'consultation onli, as appropriate)												
	SLN	Esch-sur-Alzette	Luxembourg	Rue de l'Alzette 23-25			1500					1500	
	OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
	Aggregate amount attributable to transfers of value to such Recipients												
Number of Recipients in aggregate disclosure						0	0	0	0	0			
% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed						0%	0%	0%	0%	0%	0%		
R&D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined - Article 3.04 and Schedule 2											44525	

EFPIA Member Associations

Association Pharmaceutique Luxembourgeoise (APL)

<http://www.apl-pharma.lu/accueil-fr.htm>